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INTRODUCTION
The following revised case definition for surveillance of acquired immunodefi­
ciency syndrome (AIDS) was developed by CDC in collaboration with public health 
and clinical specialists. The Council of State and Territorial Epidemiologists (CSTE) 
has officially recommended adoption of the revised definition for national reporting 
of AIDS. The objectives of the revision are a) to track more effectively the severe 
disabling morbidity associated with infection with human immunodeficiency virus 
(HIV) (including HIV-1 and HIV-2); b) to simplify reporting of AIDS cases; c) to increase 
the sensitivity and specificity of the definition through greater diagnostic application 
of laboratory evidence for HIV infection; and d) to be consistent with current 
diagnostic practice, which in some cases includes presumptive, i.e., without confirm­
atory laboratory evidence, diagnosis of AIDS-indicative diseases (e.g., Pneumocystis 
carinii pneumonia, Kaposi's sarcoma).
The definition is organized into three sections that depend on the status of 
laboratory evidence of HIV infection (e.g., HIV antibody) (Figure 1). The major 
proposed changes apply to patients with laboratory evidence for HIV infection: a) 
inclusion of HIV encephalopathy, HIV wasting syndrome, and a broader range of 
specific AIDS-indicative diseases (Section II.A); b) inclusion of AIDS patients whose 
indicator diseases are diagnosed presumptively (Section II.B); and c) elimination of 
exclusions due to other causes of immunodeficiency (Section I.A).
Application of the definition for children differs from that for adults in two ways. 
First, multiple or recurrent serious bacterial infections and lymphoid interstitial 
pneumonia/pulmonary lymphoid hyperplasia are accepted as indicative of AIDS 
among children but not among adults. Second, for children<1S months of age whose 
mothers are thought to have had HIV infection during the child's perinatal period, the 
laboratory criteria for HIV infection are more stringent, since the presence of HIV 
antibody in the child is, by itself, insufficient evidence for HIV infection because of the 
persistence of passively acquired maternal antibodies < 1 5  months after birth.
The new definition is effective immediately. State and local health departments are 
requested to apply the new definition henceforth to patients reported to them. The 
initiation of the actual reporting of cases that meet the new definition is targeted for 
September 1, 1987, when modified computer software and report forms should be in 
place to accommodate the changes. CSTE has recommended retrospective applica­
tion of the revised definition to patients already reported to health departments. The 
new definition follows:
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1987  R E V IS IO N  O F C A S E  D E F IN IT IO N  FOR A ID S  
FOR S U R V E IL L A N C E  P U R P O S E S
For national reporting, a case of AIDS is defined as an illness characterized by one 
or more of the following "indicator" diseases, depending on the status of laboratory 
evidence of HIV infection, as shown below.
I. W ith ou t Laboratory Evidence Regarding H IV Infection
If laboratory tests for HIV were not performed or gave inconclusive results (See 
Appendix I) and the patient had no other cause of immunodeficiency listed in Section
I.A below, then any disease listed in Section I.B indicates AIDS if it was diagnosed by 
a definitive method (See Appendix ¡I).
A. Causes of immunodeficiency that disqualify diseases as indicators of AIDS in
the absence of laboratory evidence for HIV infection
1. high-dose or long-term systemic corticosteroid therapy or other immuno­
suppressive/cytotoxic therapy «3 months before the onset of the indicator 
disease
2. any of the following diseases diagnosed «3 months after diagnosis of the 
indicator disease: Hodgkin's disease, non-Hodgkin's lymphoma (other 
than primary brain lymphoma), lymphocytic leukemia, multiple myeloma, 
any other cancer of lymphoreticular or histiocytic tissue, or angioimmu- 
noblastic lymphadenopathy
3. a genetic (congenital) immunodeficiency syndrome or an acquired immu­
nodeficiency syndrome atypical of HIV infection, such as one involving 
hypogammaglobulinemia
B. Indicator diseases diagnosed definitively (See Appendix II)
1. candidiasis of the esophagus, trachea, bronchi, or lungs
2. cryptococcosis, extrapulmonary
3. cryptosporidiosis with diarrhea persisting >1 month
4. cytomegalovirus disease of an organ other than liver, spleen, or lymph
nodes in a patient >1 month of age
5. herpes simplex virus infection causing a mucocutaneous ulcer that per­
sists longer than 1 month; or bronchitis, pneumonitis, or esophagitis for 
any duration affecting a patient >1 month of age
6. Kaposi's sarcoma affecting a patient < 60 years of age
7. lymphoma of the brain (primary) affecting a patient < 60 years of age
8. lymphoid interstitial pneumonia and/or pulmonary lympnoid hyperplasia 
(LIP/PLH complex) affecting a child <13 years of age
9. Mycobacterium avium complex or M. kansasii disease, disseminated (at 
a site other than or in addition to lungs, skin, or cervical or hilar lymph 
nodes)
10. Pneumocystis carinii 'pneumonia
11. progressive multifocal leukoencephalopathy
12. toxoplasmosis of the brain affecting a patient >1 month of age
r
II. W ith  Laborato ry Evidence fo r H IV  Infection
Regardless of the presence of other causes of immunodeficiency (I.A), in the 
presence of laboratory evidence for HIV infection (See Appendix I), any disease listed 
above (I.B) or below (II.A or II.B) indicates a diagnosis of AIDS.
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A. Indicator diseases diagnosed definitively (See Appendix II)
I. bacterial infections, multiple or recurrent (any combination of at least two 
within a 2-year period), of the following types affecting a child < 13 years of 
age:
septicemia, pneumonia, meningitis, bone or joint infection, or abscess of 
an internal organ or body cavity (excluding otitis media or superficial 
skin or mucosal abscesses), caused by Haemophilus, Streptococcus 
(including pneumococcus), or other pyogenic bacteria
2. coccidioidomycosis, disseminated (at a site other than or in addition to 
lungs or cervical or hilar lymph nodes)
3. HIV encephalopathy (also called "HIV dementia," "AIDS dementia,’’ or 
"subacute encephalitis due to HIV") (See Appendix (I for description)
4. histoplasmosis, disseminated (at a site other than or in addition to lungs or 
cervical or hilar lymph nodes)
5. isosporiasis with diarrhea persisting >1 month
6. Kaposi's sarcoma at any age
7. lymphoma of the brain (primary) at any age
8. other non-Hodgkin's lymphoma of B-cell or unknown immunologic phe­
notype and the following histologic types:
a. small noncleaved lymphoma (either Burkitt or non-Burkitt type) (See 
Appendix IV for equivalent terms and numeric codes used in the 
International Classification of Diseases, Ninth Revision, Clinical 
Modification)
b. immunoblastic sarcoma (equivalent to any of the following, although 
not necessarily all in combination: immunoblastic lymphoma, large­
cell lymphoma, diffuse histiocytic lymphoma, diffuse undifferentiated 
lymphoma, or high-grade lymphoma) (See Appendix IV for equivalent 
terms and numeric codes used in the International Classification of 
Diseases, Ninth Revision, Clinical Modification)
Note: Lymphomas are not included here if they are of T-cell immuno­
logic phenotype or their histologic type is not described or is described as 
"lymphocytic,’’ "lymphoblastic," "small cleaved," or "plasmacytoid lym­
phocytic"
9. any mycobacterial disease caused by mycobacteria other than M. tuber­
culosis, disseminated (at a site other than or in addition to lungs, skin, or 
cervical or hilar lymph nodes)
10. disease caused by M. tuberculosis, extrapulmonary (involving at least one 
site outside the lungs, regardless of whether there is concurrent pulmo­
nary involvement)
I I .  Salmonella (nontyphoid) septicemia, recurrent
12. HIV wasting syndrome (emaciation, "slim disease”) (See Appendix II for 
description)
B. Indicator diseases diagnosed presumptively (by a method other than those in 
Appendix II)
Note: Given the seriousness of diseases indicative of AIDS, it is generally 
important to diagnose them definitively, especially when therapy that would 
be used may have serious side effects or when definitive diagnosis is needed
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for eligibility for antiretroviral therapy. Nonetheless, in some situations, a 
patient's condition will not permit the performance of definitive tests. In other 
situations, accepted clinical practice may be to diagnose presumptively based 
on the presence of characteristic clinical and laboratory abnormalities. Guide­
lines for presumptive diagnoses are suggested in Appendix III.
1. candidiasis of the esophagus
2. cytomegalovirus retinitis with loss of vision
3. Kaposi's sarcoma
4. lymphoid interstitial pneumonia and/or pulmonary lymphoid hyperplasia 
(LIP/PLH complex) affecting a child <13 years of age
5. mycobacterial disease (acid-fast bacilli with species not identified by 
culture), disseminated (involving at least one site other than or in addition 
to lungs, skin, or cervical or hilar lymph nodes)
6. Pneumocystis carinii pneumonia
7. toxoplasmosis of the brain affecting a patient >1 month of age
III. W ith  Laboratory Evidence A gainst H IV  Infection
With laboratory test results negative for HIV infection (See Appendix I), a 
diagnosis of AIDS for surveillance purposes is ruled out unless:
A. all the other causes of immunodeficiency listed above in Section I.A are 
excluded; AND
B. the patient has had either:
1. Pneumocystis carinii pneumonia diagnosed by a definitive method (See 
Appendix II); OR
2. a. any of the other diseases indicative of AIDS listed above in Section I.B
diagnosed by a definitive method (See Appendix II); AND
b. a T-helper/inducer (CD4) lymphocyte count <400/mm3.
C O M M E N T A R Y
The surveillance of severe disease associated with HIV infection remains an 
essential, though not the only, indicator of the course of the HIV epidemic. The 
number of AIDS cases and the relative distribution of cases by demographic, 
geographic, and behavioral risk variables are the oldest indices of the epidemic, 
which began in 1981 and for which data are available retrospectively back to 1978. 
The original surveillance case definition, based on then-available knowledge, pro­
vided useful epidemiologic data on severe HIV disease ( 1 ). To ensure a reasonable 
predictive value for underlying immunodeficiency caused by what was then an 
unknown agent, the indicators of AIDS in the old case definition were restricted to 
particular opportunistic diseases diagnosed by reliable methods in patients without 
specific known causes of immunodeficiency. After HIV was discovered to be the cause 
of AIDS, however, and highly sensitive and specific HIV-antibody tests became 
available, the spectrum of manifestations of HIV infection became better defined, and 
classification systems for HIV infection were developed (2-5). It became apparent that 
some progressive, seriously disabling, and even fatal conditions (e.g., encephalop­
athy, wasting syndrome) affecting a substantial number of HIV-infected patients were 
not subject to epidemiologic surveillance, a* they were not included in the AIDS
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case definition. For reporting purposes, the revision adds to the definition most of 
those severe non-infectious, non-cancerous HIV-associated conditions that are cate­
gorized in the CDC clinical classification systems for HIV infection among adults and 
children (4 ,5 ).
Another limitation of the old definition was that AIDS-indicative diseases are 
diagnosed presumptively (i.e., without confirmation by methods required by the old 
definition) in 10%-15% of patients diagnosed with such diseases; thus, an appreciable 
proportion of AIDS cases were missed for reporting purposes (6,7). This proportion 
may be increasing, which would compromise the old case definition's usefulness as 
a tool for monitoring trends. The revised case definition permits the reporting of these 
clinically diagnosed cases as long as there is laboratory evidence of HIV infection.
The effectiveness of the revision will depend on how extensively HIV-antibody 
tests are used. Approximately one third of AIDS patients in the United States have 
been from New York City and San Francisco, where, since 1985, < 7% have been 
reported with HIV-antibody test results, compared with > 60% in other areas. The 
impact of the revision on the reported numbers of AIDS cases will also depend on the 
proportion of AIDS patients in whom indicator diseases are diagnosed presumptively 
rather than definitively. The use of presumptive diagnostic criteria varies geograph­
ically, being more common in certain rural areas and in urban areas with many 
indigent AIDS patients.
To avoid confusion about what should be reported to health departments, the term 
"AIDS’ should refer only to conditions meeting the surveillance definition, This 
definition is intended only to provide consistent statistical data for public health 
purposes. Clinicians will not rely on this definition alone to diagnose serious disease 
caused by HIV infection in individual patients because there may be additional 
information that would lead to a more accurate diagnosis. For example, patients who 
are not reportable under the definition because they have either a negative HIV- 
antibody test or, in the presence of HIV antibody, an opportunistic disease not listed 
in the definition as an indicator of AIDS nonetheless may be diagnosed as having 
serious HIV disease on consideration of other clinical or laboratory characteristics of 
HIV infection or a history of exposure to HIV.
Conversely, the AIDS surveillance definition may rarely misclassify other patients 
as having serious HIV disease if they have no HIV-antibody test but have an 
AIDS-indicative disease with a background incidence unrelated to HIV infection, such 
as cryptococcal meningitis.
The diagnostic criteria accepted by the AIDS surveillance case definition should 
not be interpreted as the standard of good medical practice. Presumptive diagnoses 
are accepted in the definition because not to count them would be to ignore 
substantial morbidity resulting from HIV infection. Likewise, the definition accepts a 
reactive screening test for HIV antibody without confirmation by a supplemental test 
because a repeatedly reactive screening test result, in combination with an indicator 
disease, is highly indicative of true HIV disease. For national surveillance purposes, 
the tiny proportion of possibly false-positive screening tests in persons with AIDS- 
indicative diseases is of little consequence. For the individual patient, however, a 
correct diagnosis is critically important. The use of supplemental tests is, therefore, 
strongly endorsed. An increase in the diagnostic use of HIV-antibody tests could 
improve both the quality of medical care and the function of the new case definition, 
as well as assist in providing counselling to prevent transmission of HIV.
\
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FIGURE I. Flow diagram for revised CDC case definition of AIDS, September 1, 1987
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Laboratory Evidence For or Against HIV infection 
1. For Infection:
When a patient has disease consistent with AIDS:
a. a serum specimen from a patient ^15 months of age, or from a child <15 
months of age whose mother is not thought to have had HIV infection during 
the child's perinatal period, that is repeatedly reactive for HIV antibody by a 
screening test (e.g., enzyme-linked immunosorbent assay [ELISA]), as long as 
subsequent HIV-antibody tests (e.g., Western blot, immunofluorescence as­
say), if done, are positive; OR
b. a serum specimen from a child < 15 months of age, whose mother is thought 
to have had HIV infection during the child’s perinatal period, that is repeatedly 
reactive for HIV antibody by a screening test (e.g., ELISA), plus increased 
serum immunoglobulin levels and at least one of the following abnormal 
immunologic test results: reduced absolute lymphocyte count, depressed CD4 
(T-helper) lymphocyte count, or decreased CD4/CD8 (helper/suppressor) ratio, 
as long as subsequent antibody tests (e.g.. Western blot, immunofluorescence 
assay), if done, are positive; OR
c. a positive test for HIV serum antigen; OR
d. a positive HIV culture confirmed by both reverse transcriptase detection and a 
specific HlV-antigen test or in situ hybridization using a nucleic acid probe; OR
e. a positive result on any other highly specific test for HIV (e.g., nucleic acid 
probe of peripheral blood lymphocytes).
2. Against Infection:
A nonreactive screening test for serum antibody to HIV (e.g., ELISA) without a
reactive or positive result on any other test for HIV infection (e.g., antibody,
antigen, culture), if done.
3. Inconclusive (Neither For nor Against Infection):
a. a repeatedly reactive screening test for serum antibody to HIV (e.g., ELISA) 
followed by a negative or inconclusive supplemental test (e.g., Western blot, 
immunofluorescence assay) without a positive HIV culture or serum antigen 
test, if done; OR
b. a serum specimen from a child < 15 months of age, whose mother is thought 
to have had HIV infection during the child's perinatal period, that is repeatedly 
reactive for HIV antibody by a screening test, even if positive by a supplemen­
tal test, without additional evidence for immunodeficiency as described above 
(in 1.b) and without a positive HIV culture or serum antigen test, if done.
A P P E N D IX  I
Vol. 38 / No. 1S MMWR 11S
A P P E N D IX

























microscopy (histology or cytology).
gross inspection by endoscopy or autopsy or by 
microscopy (histology or cytology) on a specimen 
obtained directly from the tissues affected (in­
cluding scrapings from the mucosal surface), not 
from a culture.
microscopy (histology or cytology), culture, or 
detection of antigen in a specimen obtained 
directly from the tissues affected or a fluid 
from those tissues.
culture.




clinical findings of disabling cognitive and/or 
motor dysfunction interfering with occupation or 
activities of daily living, or loss of behavioral de­
velopmental milestones affecting a child, 
progressing over weeks to months, in the 
absence of a concurrent illness or condition other 
than HIV infection that could explain the findings. 
Methods to rule out such concurrent illnesses and 
conditions must include cerebrospinal fluid exam­
ination and either brain imaging (computed to­
mography or magnetic resonance) or autopsy.
findings of profound involuntary weight loss 
>10% of baseline body weight plus either chronic 
diarrhea (at least two loose stools per day for 
3= 30 days) or chronic weakness and documented 
fever (for 2  30 days, intermittent or constant) in 
the absence of a concurrent illness or condition 
other than HIV infection that could explain the 
findings (e.g., cancer, tuberculosis, cryptosporidi- 
osis, or other specific enteritis).
•For HIV encephalopathy and HIV wasting syndrome, the methods of diagnosis described here 
are not truly definitive, but are sufficiently rigorous for surveillance purposes.
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A P P E N D IX  II I
Suggested Guidelines for Presumptive Diagnosis 
















a. recent onset of retrosternal pain on swallowing; AND
b. oral candidiasis diagnosed by the gross appearance of 
white patches or plaques on an erythematous base or 
by the microscopic appearance of fungal mycelial fila­
ments in an uncultured specimen scraped from the 
oral mucosa.
a characteristic appearance on serial ophthalmoscopic 
examinations (e.g., discrete patches of retinal whitening 
with distinct borders, spreading in a centrifugal manner, 
following blood vessels, progressing over several months, 
frequently associated with retinal vasculitis, hemorrhage, 
and necrosis). Resolution of active disease leaves retinal 
scarring and atrophy with retinal pigment epithelial mot­
tling.
microscopy of a specimen from stool or normally sterile 
body fluids or tissue from a site other than lungs, skin, or 
cervical or hilar lymph nodes, showing acid-fast bacilli of 
a species not identified by culture.
a characteristic gross appearance of an erythematous or 
violaceous plaque-like lesion on skin or mucous 
membrane.
(Note: Presumptive diagnosis of Kaposi's sarcoma should 
not be made by clinicians who have seen few cases of it.)
bilateral reticulonodular interstitial pulmonary infiltrates 
present on chest X ray for »2 months with no pathogen 
identified and no response to antibiotic treatment.
a. a history of dyspnea on exertion or nonproductive 
cough of recent onset (within the past 3 months); AND
b. chest X-ray evidence of diffuse bilateral interstitial infil­
trates or gallium scan evidence of diffuse bilateral pul­
monary disease; AND
c. arterial blood gas analysis showing an arterial p02 of 
<70 mm Hg or a low respiratory diffusing capacity 
(<80% of predicted values) or an increase in the 
alveolar-arterial oxygen tension gradient; AND
d. no evidence of a bacterial pneumonia.
14S MMWR August 14. 1987
toxoplasmosis 
of the brain
a. recent onset of a focal neurologic abnormality consis­
tent with intracranial disease or a reduced level of con­
sciousness; AND
b. brain imaging evidence of a lesion having a mass ef­
fect (on computed tomography or nuclear magnetic 
resonance) or the radiographic appearance of which is 
enhanced by injection of contrast medium; AND
c. serum antibody to toxoplasmosis or successful 
response to therapy for toxoplasmosis.
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Equivalent Terms and International Classification 
of Disease (ICD) Codes for AIDS-Indicative Lymphomas
A P P E N D IX  I V
The following terms and codes describe lymphomas indicative of AIDS in 
patients with antibody evidence for HIV infection (Section II.A.8 of the AIDS case 




lymphoma (malignant): histiocytic (diffuse) reticulum cell sarcoma: 
pleomorphic cell type or not otherwise specified 
200.2 Burkin's tumor or lymphoma
malignant lymphoma, Burkin's type
ICD-0 (Oncologic Histologic Types 1976)
Codes Terms
9600/3 Malignant lymphoma, undifferentiated call type
non-Burkitt's or not otherwise specified 
9601/3 Malignant lymphoma, stem cell type
stem cell lymphoma 
9612/3 Malignant lymphoma, immunoblastic type
immunoblastic sarcoma, immunoblastic lymphoma, or immunoblas­
tic lymphosarcoma 
9632/3 Malignant lymphoma, centrobiastic type
diffuse or not otherwise specified, or germinoblastic sarcoma: diffuse 
or not otherwise specified 
9633/3 Malignant lymphoma, follicular center cell, non-cleaved
diffuse or not otherwise specified 
9640/3 Reticulosarcoma, not otherwise specified
malignant lymphoma, histiocytic: diffuse or not otherwise specified 
reticulum cell sarcoma, not otherwise specified malignant 
lymphoma, reticulum cell type 
9641/3 Reticulosarcoma, pleomorphic cell type
malignant lymphoma, histiocytic, pleomorphic cell type reticulum cell 
sarcoma, pleomorphic cell type 
9750/3 Burkin's lymphoma or Burkin's tumor
malignant lymphoma, undifferentiated, Burkitt's type malignant lym­
phoma, lymphoblastic, Burkitt's type
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